Clinical Trials Browser

adavosertib × Gynecologic × Clear all

NCT02659241 2026-04-15

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Fallopian Tube Neoplasms

NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

124 enrolled 17 charts

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Phase 2 Active not recruiting

Uterine Neoplasms

NCT03345784 2024-02-20

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Phase 1 Terminated

10 enrolled 15 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms, Carcinoma, Endometrioid

NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

95 enrolled 61 charts

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Phase 2 Completed

136 enrolled 15 charts

Ovarian Neoplasms

NCT01076400 2023-09-18

MK-1775-008

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

NCT01164995 2023-09-07

M10MKO

Phase 2 Completed

Carcinoma, Ovarian Epithelial

NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02610075 2023-07-03

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Phase 1 Completed

Ovarian Neoplasms